| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | -0.053 | 0.1 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | -0.043 | 0.1 |
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | -0.059 | 0.1 |
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | -0.044 | 0.2 |
| mRNA | OSI-027 | CTRPv2 | pan-cancer | AAC | -0.049 | 0.2 |
| mRNA | Curcumin | CTRPv2 | pan-cancer | AAC | -0.047 | 0.2 |
| mRNA | BCL-LZH-4 | CTRPv2 | pan-cancer | AAC | 0.073 | 0.2 |
| mRNA | SNS-032 | CTRPv2 | pan-cancer | AAC | -0.049 | 0.2 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.048 | 0.2 |
| mRNA | navitoclax:pluripotin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.049 | 0.2 |